Table 1 Characteristics of experienced patients not receiving MVC at the time of tropism test performance
Total (n = 366) | MVC prescription (n = 110) | No MVC prescription (n = 256) | p | |
|---|---|---|---|---|
Test performance before 2011 | 164 (44.8) | 75 (68.2) | 89 (34.8) | < 0.01 |
Age (years) | 47 (10.9) | 49 (10) | 47 (11.3) | 0.05 |
Male sex | 263 (71.9) | 80 (72.7) | 183 (71.5) | 0.81 |
Risk group | 0.13 | |||
Heterosexual | 175 (47.8) | 50 (45.5) | 125 (48.8) | |
Homosexual | 145 (39.6) | 50 (45.5) | 95 (37.1) | |
Other | 46 (12.6) | 10 (9.1) | 36 (14.1) | |
CDC stage | 0.03 | |||
A | 185 (50.6) | 46 (41.8) | 139 (54.3) | |
B | 84 (22.9) | 34 (30.9) | 50 (19.5) | |
C | 97 (26.5) | 30 (27.3) | 67 (26.2) | |
CD4 count (/mm3) | 515.9 (286.5) | 539.7 (262.5) | 505.8 (295.9) | 0.27 |
Undetectable viral load | 155 (42.3) | 52 (33.5) | 103 (66.5) | 0.21 |
Time between ART initiation and tropism (years) | 9.9 (6.1) | 10.9 (6) | 9.4 (6.1) | 0.03 |
Time between last ART change and tropism (years) | 2.2 (2.2) | 2.4 (2) | 2.1 (2.3) | 0.09 |
Number of previous ART regimens | 6 (5.3) | 7.9 (7.1) | 5.2 (4) | < 0.01 |
Number of ART families with resistance | 1.1 (1) | 1.2 (1.1) | 1.1 (0.9) | 0.23 |
Reason for tropism performance | < 0.01 | |||
Virological failure | 170 (46.4) | 38 (34.5) | 132 (51.6) | |
Side effect or interaction | 128 (35) | 50 (45.5) | 78 (30.5) | |
Neurological diffusion | 14 (3.8) | 7 (6.4) | 7 (2.7) | |
Sparing strategy or simplification | 41 (11.2) | 10 (9.1) | 31 (12.1) | |
Immunological failure | 13 (3.6) | 5 (4.6) | 8 (3.1) |